15 news items
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
weighing 63kg or greater adds to Kevzara's position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
REGN
SNY
31 May 24
-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually
FDA Extends Priority Review Deadline For Regeneron Pharmaceuticals And Sanof's Dupixent For The Treatment Of COPD Patients With Type 2 Inflammation To September 2024
REGN
SNY
31 May 24
License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN
31 May 24
with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. The European Commission is expected to announce a final
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN
31 May 24
of Dupixent (dupilumab) in the European Union (EU) as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease (COPD
1ktfwxhw1viy qph
REGN
31 May 24
with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action date is September 27, 2024. The FDA did not raise any concerns
3spvi3 25c
REGN
31 May 24
with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action date is September 27, 2024. The FDA did not raise any concerns
nn7fi29hti6q9uwe0zd8vxjlu
REGN
SNY
20 May 24
% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
3ioa5mexalyc55ywn qvg0go1qx
REGN
20 May 24
exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type
u4qd41q51k6l5jmghrk3fi66hqglb1b0lvauivr8hjmf5c9d 3jm35h
REGN
20 May 24
to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
cgbdrw1je9k1f7bhkp50v79szvz11
REGN
SNY
13 May 24
hiqv 7eydr2en3jh8zanw7m7y0z8j
REGN
13 May 24
12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). The target action date for the FDA decision
ipaar188c4ft6cfup7ezvmoiex23scys9 9q8nx6
REGN
2 May 24
Application (sBLA) for Dupixent as an add-on maintenance treatment in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD
5ijzxvv
REGN
24 Apr 24
Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
iudc4z2nmryu7efv64s
AMGN
AZN
REGN
17 Apr 24
an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive
- Prev
- 1
- Next